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Abstract
Background—Congenital heart defects (CHDs) are among the most prevalent and serious of
birth defects. Multiple maternal factors are thought to contribute to CHD development including
folate intake. Maternal DNA methylation, which is dependent on folate metabolism, may impact
the risk of CHDs.
Objective—Our study was designed to determine whether maternal long interspersed nucleotide
elements-1 (LINE-1) DNA hypomethylation is associated with increased occurrence of non-
syndromic CHDs and whether maternal folate-dependent metabolites are correlated with DNA
methylation status.
Design—Using a case-control study design, we measured global DNA methylation status among
mothers whose pregnancies were affected by non-syndromic CHDs (n=180) and mothers of
unaffected pregnancies (n=187). Methylation of LINE-1 was used as a surrogate marker of global
DNA methylation status. The association between DNA methylation and CHD risk was
determined while adjusting for selected lifestyle factors.
Results—LINE-1 DNA methylation was significantly lower in cases compared with controls
(p=0.049). After covariate adjustments, a significant difference between cases and controls
remained (p=0.010). Among women with LINE-1 methylation in the lowest decile of DNA
methylation, the estimated risk of having a CHD-affected pregnancy was almost twice that of
women in all other deciles (OR=1.91; 95% CI: 1.03, 3.58).
Conclusions—Our findings indicate that maternal LINE-1 DNA hypomethylation is associated
with an increased risk of CHDs. Future studies investigating the association between maternal
DNA methylation patterns and CHDs should be pursued.
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INTRODUCTION
Congenital heart defects (CHDs) are the most prevalent and serious of birth defects,
occurring in 8 to 10 of every 1,000 live births in the United States (Moller et al., 1993). The
molecular mechanisms leading to CHDs are complex, and the majority of cardiac
malformations that occur in humans are of unknown etiology. Multiple factors including
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genetic susceptibilities, epigenetic mechanisms, and environmental influences may
contribute to the development of non-syndromic CHDs.
Maternal folate deficiency and alterations in one-carbon metabolism have been shown to
increase the risk for several birth defects including CHDs (Hobbs et al., 2005; Hobbs et al.,
2010; Rosenquist and Finnell, 2001; Shaw et al., 1995; van Driel et al., 2008). During
pregnancy there is an increased requirement for folate-dependent nucleotide synthesis and
DNA methylation (Oommen et al., 2005), and previous studies suggest that altered DNA
methylation may be an underlying mechanism in the development of birth defects (Blom et
al., 2006; Li et al., 2005; Okano et al., 1999). Various maternal factors such as diet
(Waterland and Jirtle, 2003), genotype (Li et al., 2005), and environmental exposures
(Ozanne and Constancia, 2007) have been implicated in abnormal fetal development. These
same factors have been shown to affect DNA methylation patterns (Cooney et al., 2002;
Candiloro and Dobrovic, 2009; Baccarelli et al., 2009). A combination of maternal genes
and environmental exposures may alter the intrauterine environment and thereby modify the
fetal phenotype (Furness et al., 2008; MacLennan et al., 2004). In addition to genetic
variants, alterations in epigenetic phenomena, such as DNA methylation, could play a
crucial role in determining the fetal phenotype. The impact of maternal genetics and
epigenetics in the intrauterine environment and subsequent fetal development is not well
understood. Little is known about the association between CHDs and maternal DNA
methylation despite evidence linking CHDs with maternal folate supplementation and
alterations in folate related pathways (Shaw et al., 1995).
DNA methylation is a form of epigenetic gene regulation. The added methyl group can
interfere with transcription factor binding, thereby regulating transcription (Comb and
Goodman, 1990). Additionally, DNA methylation changes can affect histone modifications
and chromatin structure, which can alter gene expression. Hypomethylation of DNA has
been reported to contribute to chromosome instability and to alter gene expression, cell
differentiation, and apoptosis during embryogenesis (Ehrlich, 2003). Additionally, mutations
in the murine DNA methyltransferase (DNMT) gene have been shown to result in
embryonic lethality (Li et al., 1992), implicating the importance of DNA methylation in
embryogenesis.
The long interspersed nucleotide element (LINE-1) constitutes 17% to 25% of the human
genome, with an estimate of over 500,000 LINE-1 elements dispersed throughout the
genome (Kazazian, Jr., 2004). Methylation of LINE-1 has been shown to correlate with
global DNA methylation (Weisenberger et al., 2005; Yang et al., 2004). Demethylation of
these elements, and subsequent activation of retrotransposon activity, can lead to alterations
in expression in various genes (Sassaman et al., 1997). LINE-1 methylation of DNA isolated
from peripheral blood cells has been shown to be a potential marker of exposure and disease
(Bollati et al., 2007; Hsiung et al., 2007).
In the present study we sought to determine if maternal LINE-1 DNA hypomethylation was
associated with the occurrence of CHD-affected pregnancies. We also attempted to




The National Birth Defects Research and Prevention Study (NBDPS) is an ongoing multi-
site population-based case-control study investigating the etiology of 30 non-syndromic
birth defects. The NBDPS is the largest case-control study of birth defects ever conducted in
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the United States and has been previously described (Yoon et al., 2001). For the current
study, case women were Arkansas residents who participated in the NBDPS and who
delivered a singleton live birth with a non-syndromic CHD. Cases for whom the pregnancy
was also affected by a known single-gene disorder, chromosomal abnormality, or syndrome
were excluded from the NBPDS. All diagnostic tests on cardiac NBDPS case infants were
reviewed by a pediatric cardiologist to ensure uniform criteria were used for diagnoses. To
be eligible for the study described in this manuscript, case infants were required to have at
least one cardiac lesion, which included conotruncal, septal, and/or obstructive lesions.
Using a classification system developed for the NBDPS, which incorporated three
dimensions of cardiac phenotype, cardiac complexity, and extracardiac anomalies (Botto et
al., 2007), case women for the current study included those who carried fetuses with simple
and association CHDs. Control women were Arkansas residents who had a singleton live
birth without birth defects during the same period as the cases, who participated in the
NBDPS, and were randomly selected from birth certificate data or hospital discharge logs.
Cases and controls spoke either English or Spanish. Blood samples were collected by nurses
during home visits in Arkansas that occurred between 2001 and 2008; the research nurses
obtained blood samples by venipuncture after acquiring written consent. Blood samples
were collected after pregnancy. All participants signed informed consent approved by the
University of Arkansas for Medical Sciences Institutional Review Board.
From 548 cases and 243 controls meeting the inclusion criteria, 180 cases and 187 controls
were randomly selected using the random number generator in Stata statistical package
version 11 (StataCorp, College Station, TX).
Covariates
Information regarding selected lifestyle factors was obtained from NBDPS-structured
computer-assisted telephone interviews and by in-home interviews conducted at the time of
blood draw by a research nurse using a Block Abbreviated Food-Frequency Questionnaire
(Block et al., 1990). The information on covariates reflects up to one month prior to the
visit. Covariates were selected based on their potential effects on DNA methylation status
and the occurrence of heart defects; covariates included were age, race, body mass index
(BMI), and the use of multivitamins, cigarettes, and alcohol.
Sample preparation and processing
Fasting blood samples were collected in EDTA-Vacutainer tubes and immediately chilled on
ice before they were centrifuged at 4,000 × g for 10 minutes at 4°C to obtain blood plasma.
The blood cell pellets and plasma samples were stored at −80°C until DNA isolation and
high performance liquid chromatography (HPLC) analyses.
DNA isolation and bisulfite treatment
DNA was isolated from frozen blood samples according to the manufacturer’s protocol for
the PureGene DNA isolation kit (Gentra Systems, Minneapolis, MN). Genomic DNA was
quantified using the ABI TaqMan RNase P Quantification Kit (Applied Biosystems, Forest
City, CA) according to the manufacturer’s protocol. Using the EZ DNA Methylation-Direct
Kit (Zymo Research, Orange Country, CA), 500 ng of genomic DNA underwent sodium
bisulfite modification. The converted DNA was resuspended in 20 µl of TE buffer and
stored at −80°C until the samples were ready for analysis.
DNA methylation assessment with Methylight
Methylight methodology provides a quantitative methylation-specific PCR assay that allows
rapid analysis of methylated and unmethylated alleles via fluorescent detection. The merits
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of this technology have been well-characterized (Weisenberger et al., 2005; Ogino et al.,
2006; Eads et al., 2000). This process uses bisulfite treatment of DNA, which converts
unmethylated cytosines to uracils, leaving the methylated cytosines protected from this
conversion (Frommer et al., 1992). Since the primers lack CpG sites, the methylated and
unmethylated primer binding sites will be identical after bisulfite conversion. The specificity
of the assay occurs during probe hybridization by the use of separately labeled probes. The
improved sequence specificity allows relative quantification of methylated and
unmethylated alleles in a genomic DNA sample (Zeschnigk et al., 2004). The VIC-labeled
probe hybridizes to the sequence of the methylated LINE-1 allele, and the FAM-labeled
probe hybridizes to the sequence of the unmethylated LINE-1 allele. Once the probes bind to
their selected sites, they are cleaved by Taq polymerase during the PCR reaction, separating
the fluorescent tag from the quencher. The amount of resulting fluorescence detected, either
VIC or FAM, is directly proportional to the amount of PCR product generated from
methylated or unmethylated DNA, respectively (Eads et al., 2000). The probe sequences
cover multiple CpG sites within the LINE-1 repetitive sequences, which reflect genome-
wide methylation density.
Generation of methylated and unmethylated DNA standards
Methylated and unmethylated standards were generated in order to test the specificity of the
PCR reactions. Fully methylated DNA was generated from DNA provided by healthy
volunteers. The DNA was incubated with M.SssI enzyme (New England Biolabs, Ipswich,
MA) at a concentration of 1U/µg of DNA and with 0.16 mM of SAM overnight at 37°C.
Extra SAM and M.SssI enzyme was added at the same concentrations for a second overnight
incubation at 37°C. The samples were stored at −20°C. To generate unmethylated DNA,
healthy volunteer DNA was amplified using the Sigma Whole Genome Amplification
(WGA2) kit (Sigma-Aldrich, St. Louis, MO). The manufacturer’s protocol was used. The
product was stored at −20°C. The mixing of methylated and unmethylated DNA as
standards for DNA methylation assays has been used successfully by other research groups
(Richards, 2006; Yideng et al., 2007).
Real Time Methylation-Specific PCR (Methylight)
PCR reactions were performed with a final reaction volume of 25 µl in 96-well sealed plates
on the ABI 7900 HT Real Time PCR System (Applied Biosystems, Forest City, CA).
Samples contained 12.5 µl of TaqMan Universal Master Mix, 2 µl of bisulfite-treated DNA,
2.5 µM of each of the primers, and 150 nM of TaqMan MGB probes corresponding to the
methylated and unmethylated LINE -1 sequence after bisulfite treatment. Real-Time PCR
reactions were performed simultaneously on the same 96-well plate. The cycle conditions
for the LINE-1 assay were as follows: Initial denaturation at 95°C for 10 minutes to activate
Taq polymerase was followed by 50 cycles of denaturation at 94°C for 15 seconds followed
by 60°C for 1.5 minutes. Equal PCR efficiency between plates was ensured by including a
duplicated sample that contained equal amounts of methylated and unmethylated DNA. The





Generation of percent DNA methylation values
The amount of methylated and unmethylated DNA was calculated for each sample by
interpolation of a standard curve that was established for both methylated and unmethylated
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DNA. Serial dilutions of methylated and unmethylated DNA were prepared in order to
ensure that all sample values could be interpolated from the standard curve. The percent
methylation was calculated by dividing the amount of methylated DNA by the amount of
total DNA (methylated plus unmethylated DNA). Each sample was assayed in duplicate and
the replicates achieved strong correlation (r=0.84).
Biomarker measurements
Total plasma homocysteine, methionine, SAM, and SAH were determined by HPLC as
described elsewhere by our research group (Hobbs et al., 2005). The methodologic details
for metabolite elution and electrochemical detection were described previously (Melnyk et
al., 1999; Melnyk et al., 2000). Plasma folic acid concentrations were measured by using
Quantaphase II radioimmunoassay kit according to the manufacturer’s protocol (Biorad
Laboratories, Hercules, CA).
Statistical analysis
Selected characteristics of case and control subjects were compared with a Fisher’s exact
test for categorical variables. LINE-1 methylation values for cases and controls were
compared using a non-parametric two-sample Wilcoxon rank-sum test. The Wilcoxon rank-
sum test was also used to compare LINE-1 methylation between smokers and non-smokers,
and between those with normal BMIs (18.5–24.9) and obese individuals (≥30).
Multivariable logistic regression was used to compute odds ratios and 95% confidence
intervals for the association between LINE-1 methylation and case-control status while
adjusting for age, race, vitamin supplementation, smoking, alcohol consumption, and BMI.
The frequency distributions of LINE-1 methylation values for cases and controls were
graphically examined and compared using a quantile-quantile (Q-Q) plot and a frequency
histogram. If the distribution of methylation values was similar for cases and controls, the
Q-Q plot would closely follow the diagonal line x=y, whereas deviations from the diagonal
line indicate different distributions of methylation values between cases and controls. The
relationships between LINE-1 DNA methylation and selected homocysteine-methionine
pathway biomarkers were determined by computing Spearman’s partial correlation
coefficient after covariate adjustments. The comparison between cases and controls for
selected biomarkers was conducted using a multiple linear regression model adjusting for
the covariates previously listed.




LINE-1 DNA methylation was measured in 367 participants (180 cases and 187 controls).
Table 1 presents selected characteristics of study participants. The majority of cases (61.7%)
and controls (60.4%) were less than 30 years old. The study population consisted mostly of
Caucasian women. The frequencies of most characteristics were similar between cases and
controls. However, smoking was significantly more prevalent in cases (30.0%) than in
controls (18.7%; p=0.015), and the median time interval between the end of pregnancy and
blood draw was significantly longer for controls (16.5 months; range = 0.13–65.3 months)
than for cases (15.4 months; range = 4.3–63.3 months; p=0.035). Additional analyses to
determine if smoking and the interval between end of pregnancy and blood draw were
confounders was conducted. Specifically, neither smoking nor time of blood draw was
associated with LINE-1 methylation status in either cases, controls, or both (data not
shown).
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Plasma concentrations of selected metabolites involved in one-carbon metabolism are
summarized in Table 2. As we have previously reported, we observed significant differences
between cases and controls for the biomarkers analyzed after adjusting for multiple
covariates. When compared to controls, cases had higher mean concentrations of
homocysteine and SAH and lower mean concentrations of methionine, SAM, the SAM/SAH
ratio, and folate. The metabolite concentrations in the cases were all reflective of a
decreased cellular methylation capacity.
LINE-1 DNA methylation analysis
Table 3 presents summary statistics of LINE-1 DNA methylation in cases and controls.
DNA methylation was significantly lower (hypomethylation) in cases when compared to
controls (p=0.049). To control for potential confounders, we constructed a model to adjust
for age, race, body mass index (BMI), and the use of multivitamins, cigarettes, and alcohol.
The significant association between LINE-1 methylation and case/control status remained
after covariate adjustment (p=0.010).
To further explore the relationship between LINE-1 methylation and CHDs in our
population, we conducted analyses stratified for smoking and obesity. Smoking was more
prevalent among cases than controls, and thus we stratified our analyses by smoking status.
We did not observe a significant relationship among LINE-1 methylation and smoking
status (p=0.974). We also compared LINE-1 methylation among individuals with a normal
BMI and obese individuals, but the result was not statistically significant (p=0.557).
To determine if the associations between DNA methylation and cardiac defects were related
to specific cardiac phenotypes, an analysis stratified by cardiac phenotypes was conducted.
Cardiac phenotypes included conotruncal, septal, and obstructive defects. Cases that had
more than one cardiac defect type were included in all relevant strata. Due to a small number
of cases, the 14 cases that did not fall within one of the main defect groups were excluded
from the stratified analysis. Among cases, 47.2% had atrial or ventricular septal defects,
35.4% had right- and left-sided obstructive defects, and 16.7% had conotruncal defects.
After covariate adjustment, LINE-1 methylation was significantly lower among women with
pregnancies affected by septal defects (mean=81.26, SD=11.44) compared to controls
(mean=83.64, SD=10.16; p=0.043). LINE-1 methylation was lower among conotruncal and
obstructive cases compared to controls (p=0.085 and 0.086, respectively), but these results
did not achieve statistical significance. LINE-1 methylation was lowest among conotruncal
cases (mean=80.0%, SD=11.2). Because LINE-1 methylation did not deviate significantly
between cardiac phenotypes, cases were combined for subsequent analyses to maximize
power to test study hypotheses. A Q-Q plot and histograms were created to examine and
compare the frequency distributions of LINE-1 methylation in cases and controls (Figure 1).
Both the Q-Q plot and the histogram revealed marked deviations in methylation between
cases and controls at the lower values of the distribution.
Based on these plots, LINE-1 DNA methylation was further compared between cases and
controls by computing adjusted odds ratios and 95% confidence intervals at various cutoffs
on the basis of methylation levels within controls (Table 4).
Of the 180 cases, 55 (30.6%) cases had with LINE-1 methylation values below the 20th
percentile of controls and 33 (18.3%) cases had LINE-1 methylation values below the 10th
percentile of controls, indicating a shift to lower values in LINE-1 methylation in cases
relative to controls. Women in this bottom decile were almost twice as likely to have a
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CHD-affected pregnancy compared to women above this decile (OR= 1.91; 95% CI: 1.03,
3.58).
These findings suggested that a lower DNA methylation status may be associated with an
increased risk of CHDs.
LINE-1 methylation and selected metabolites correlation
The correlations between LINE-1 DNA methylation and selected plasma metabolites were
computed to determine if metabolites were predictive of DNA methylation status among
cases and controls (Table 5). Homocysteine had the strongest correlation with LINE-1
methylation. As LINE-1 DNA methylation decreased, total homocysteine concentration
increased, resulting in a negative correlation (Spearman‘s r=−0.135, p=0.013). A separate
model for cases and controls correlating LINE-1 and homocysteine was computed for cases
and controls. The slopes from each model were not significantly different (data not shown).
Concentrations of methionine, s-adenosylmethionine (SAM), s-adenosylhomocysteine
(SAH), and folate were not significantly correlated with LINE-1 methylation status.
DISCUSSION
To our knowledge, our findings represent the first published study in which DNA
methylation of LINE-1 was compared between mothers of CHD-affected pregnancies and
controls. DNA hypomethylation of the LINE-1 repetitive element was observed in case
mothers when compared to control mothers. Placement in the lowest deciles of methylation
resulted in an increased risk of CHD-affected pregnancies. LINE-1 DNA methylation status
was not strongly correlated with selected methionine pathway plasma metabolites.
The magnitude of difference between case and control LINE-1 methylation was relatively
small compared to differences reported in other disease models, for example, between
normal and tumor tissue samples (Iacopetta et al., 2007). However, a small magnitude of
difference in peripheral blood LINE-1 methylation was observed in a previous case/control
study (Hsiung et al., 2007). During pregnancy, increases in cellular proliferation and one-
carbon metabolism are required for uterine enlargement, expansion of blood volume,
placental development, and fetal growth (Bruinse and van den, 1995; Tamura and Picciano,
2006). For the developing embryo, the increased demand for methyl groups for nucleotide
synthesis and DNA methylation may result in a small threshold between sufficient and
insufficient methylation capacity. Insufficient methylation capacity may cause deleterious
changes in developmental programming resulting in CHDs and other birth defects.
LINE-1 methylation has shown to be significantly correlated with global methylation levels
measured by HPLC in cancer models. Additionally, demethylation of repetitive elements
can ultimately lead to aberrant expression in other genes (Asada et al., 2006). It has been
suggested that hypomethylation of repetitive elements may influence genomic instability
and may consequently cause genome instability in the progeny (Filkowski et al., 2010).
Although speculation regarding transgenerational epigenetic inheritance exists, the majority
of evidence exists in animal models (Morgan and Whitelaw, 2008). Correlations between
parent-child pairs in LINE-1 methylation suggest the possibility of transgenerational
epigenetic inheritance being associated with disease risk (Mirabello et al., 2010).
A decrease in the incidence of CHDs and neural tube defects (NTDs) can be achieved with
preconception folic acid supplementation (Hobbs et al., 2010). The shared biological
sensitivity for these separate anatomical sites is thought to involve their common neural
epithelial cell origin (Rosenquist and Finnell, 2001). Thus, CHDs and NTDs may share
multiple similar pathophysiological pathways. It has been postulated that inhibition of the
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methylation cycle may contribute to the development of NTDs through the disruption of
crucial reactions involving the methylation of DNA and other biomolecules (Dunlevy et al.,
2006). Recent studies have shown an increased risk of NTDs with decreased LINE-1 and
global methylation status (Chen et al., 2010; Wang et al., 2010). These studies provide
evidence that genomic methylation may play a role in the development of NTDs. Additional
studies to confirm the role of DNA methylation in CHD risk should be pursued as well.
The LINE-1 repetitive element has been used as a measure for genomic methylation status
for methylation-specific PCR assays (Hsiung et al., 2007; Iacopetta et al., 2007; Yideng et
al., 2007) and widely used in pyrosequencing assays (Wang et al., 2010; Figueiredo et al.,
2009; Bollati et al., 2007). LINE-1 methylation patterns appear to be tissue-specific and vary
depending on cell type (Chalitchagorn et al., 2004), thus the values obtained from
methylation studies may vary greatly depending on the processed biological sample and the
assay performed. The range of LINE-1 methylation values presented in this study are
consistent with two previously published studies assessing LINE-1 methylation (Iacopetta et
al., 2007; Wilhelm et al., 2010). We observed a large proportion of LINE-1 methylation
values greater than 80%, and this observation is in agreement with other published studies
(Iacopetta et al., 2007; Jin et al., 2009; Richards et al., 2009).
An inverse correlation between cord plasma homocysteine and LINE-1 methylation in
humans has been recently shown (Fryer et al., 2009). We also observed a modest inverse
correlation between LINE-1 methylation and plasma homocysteine. The lack of a strong
correlation between LINE-1 methylation and selected biomarkers may be explained by the
hypothesis proposed by Kim (Kim, 2005) stating that the effects of folate deficiency and the
supply of DNA methyl groups may be gene- and site-specific and dependent on the cell
type, organ, stage of transformation, and degree and duration of folate depletion. Previous
studies have also shown a lack of correlation between LINE-1 methylation and methionine
pathway metabolites (Figueiredo et al., 2009; Wang et al., 2010). Since folate pathway
metabolites lacked strong correlation with LINE-1 methylation, we postulate that the
genomic methylation differences observed may be due to other unmeasured factors. Single
nucleotide polymorphisms, additional metabolites, and environmental exposures are factors
that may explain the alterations in DNA methylation observed in the study.
Certain methodological limitations of this study should be considered. Subjects were
enrolled in a case-control study after completion of pregnancy. Given the rare prevalence of
CHDs, the resources and sample size required to conduct a cohort study among women
enrolled before conception and followed to the completion of pregnancy are enormous; thus,
case-control design is the preferred epidemiological design for rare outcomes. Thus, we did
not measure DNA methylation changes during pregnancy and fetal organogenesis, when
changes in methylation status would be expected to have the greatest effect. We have
previously stated that the plasma biomarker concentrations in our study design may not
represent biomarker concentrations at the time of organogenesis, but may identify women
who have persistent metabolic imbalances (Hobbs et al., 2005). It has been shown that
homocysteine concentrations and dietary patterns remain relatively stable from
preconception throughout pregnancy and postpartum (Cikot et al., 2001; Cuco et al., 2006).
We found no correlation between maternal age and LINE-1 methylation (data not shown).
Thus, LINE-1 methylation observed after pregnancy may reflect stable adult profiles that
were present at the time of conception. Another limitation of our experimental design is that
only allowed the analysis of only fully methylated and unmethylated alleles in the LINE-1
repetitive element. If partial methylation occurs at the level of probe discrimination, the
sequence derived after bisulfite conversion is recognized by neither of the two probes. Thus,
partial methylation may affect the ability of the assay to detect global methylation density
via the amplification of the LINE-1 consensus sequence. This design is in contrast to other
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methods that measure the methylation level at several single CpG sites. An advantage of
Methylight is its high sensitivity and low input DNA requirement, but it is prone to higher
variability that other methods (Aparicio et al., 2009).
To our knowledge, our study is the first to measure maternal DNA methylation in a case-
control study of CHDs. The study has notable strengths including the analysis of DNA
methylation in a relatively large population of mothers in which information regarding
various lifestyle factors and plasma metabolite concentrations were available. Our study
design allowed the assessment of the relationship between LINE-1 DNA methylation and
the risk of CHDs. Our findings indicate maternal LINE-1 hypomethylation is associated
with an increased risk of CHD-affected pregnancies. Alterations in maternal DNA
methylation converge with evidence from previous studies that indicate folate-dependent
genetic and metabolic susceptibilities increase the risk of CHDs. These results suggest that
future studies involving repetitive, global, and gene-specific maternal DNA methylation and
CHDs are warranted. The ability to possibly restore aberrant DNA methylation to normal
levels via nutritional intervention makes DNA methylation an attractive potential therapeutic
target. Identification of genetic and epigenetic profiles associated with an increased risk of
CHDs may add new dimensions to assessing preconception risk and may prove to be
instrumental in elucidating the mechanisms that underlie the development of CHDs.
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Figure 1. Quantile-quantile graph and frequency histogram of long interspersed nucleotide
elements (LINE-1) methylation by case/control status
A) A quantile-quantile plot showing that the distribution of quantiles between cases and
controls deviates from equality towards the lower values of LINE-1 methylation. Deviations
from the line indicate different distributions among the two groups. B) A frequency
histogram showing that cases and controls are distributed differently at higher and lower
LINE-1 methylation values. Cases are more prevalent at lower methylation values, and
controls are more prevalent at higher methylation values.
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Table 1




n (%) P valuea
Age (y)
   <30 111 (61.7) 113 (60.4)
   ≥30 69 (38.3) 74 (39.6) 0.831
Race
   Caucasian 136 (75.6) 148 (79.1)
   African American 32 (17.8) 22 (11.8)
   Others 12 (6.7) 17 (9.1) 0.205
Smoker
   Missing 0 (0.0) 1 (0.5)
   No 126 (70.0) 151 (80.7)
   Yes 54 (30.0) 35 (18.7) 0.015
Alcohol drinker
   Missing 1 (0.6) 2 (1.1)
   No 93 (51.7) 85 (45.4)
   Yes 86 (47.8) 100 (53.5) 0.294
Vitamin supplementation
   Missing 0 (0.0) 1 (0.5)
   No 99 (55.0) 111 (59.4)
   Yes 81 (45.0) 75 (40.1) 0.400
Maternal education
   Missing 5 (2.8) 0 (0.0)
   High school or less 83 (46.1) 79 (42.2)
   College education or higher 92 (51.1) 108 (57.8) 0.342
Household income
   Missing 13 (7.2) 12 (6.4)
   Less than $10,000 34 (18.9) 23 (12.3)
   $10,000–$30,000 60 (33.3) 55 (29.4)
   $30,001–$50,000 39 (21.7) 51 (27.3)
   More than $50,000 34 (18.9) 46 (24.6) 0.137
Body Mass Index (BMI) (kg/m2)
   Missing 8 (4.4) 9 (4.8)
   Underweight (<18.5) 3 (1.7) 6 (3.2)
   Normal (18.5–24.9) 57 (31.7) 78 (41.7)
   Overweight (25.0–29.9) 44 (24.4) 34 (18.2)
   Obese (≥30.0) 68 (37.8) 60 (32.1) 0.118
a
Fisher's exact test for categorical variables.
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Table 4
Adjusted OR and 95% CI for the association between case and control status at long interspersed nucleotide





n (%) Adjusted ORa (95% CI)
<78.5 (30th) 64 (35.6%) 58 (31.0%) 1.24 (0.78, 1.96)
<74.7 (20th) 55 (30.6%) 38 (20.3%) 1.72 (1.04, 2.84)
<69.9 (10th) 33 (18.3%) 20 (10.7%) 1.91 (1.03, 3.58)
a
Adjusted for age, race, vitamin supplementation, smoking, alcohol consumption, and BMI. OR=Odds Ratio; 95% CI=95% Confidence Interval.
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Table 5
Spearman partial correlation between long interspersed nucleotide elements (LINE-1) methylation and
selected biomarkersa
LINE-1 Methylation








SAM, S-adenosylmethionine; SAH, S-adenosylhomocysteine.
b
Adjusted for age, race, vitamin supplementation, smoking, alcohol consumption, and body mass index (BMI).
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